Ye Chenglin, Li Peng, Chen Boxu, Mo Yong, Huang Qianrong, Li Qiuyun, Hou Qinhan, Mo Ligen, Yan Jun
Department of Neurosurgery, Guangxi Medical University Cancer Hospital, Nanning, China.
Department of Neurosurgery, Institute of Brain Diseases, Nanfang Hospital of Southern Medical University, Guangzhou, China.
Front Genet. 2024 Oct 9;15:1466617. doi: 10.3389/fgene.2024.1466617. eCollection 2024.
Formyl peptide receptor 3 (FPR3) is known to have implications in the progression of various cancer types. Despite this, its biological significance within pan-cancer datasets has yet to be investigated. In this investigation, we scrutinized FPR3's expression profiles, genetic alterations, prognostic significance, immune-related characteristics, methylation status, tumor mutation burden (TMB), and microsatellite instability (MSI) across different types of cancer. We utilized TISCH's single-cell data to identify immune cells closely associated with FPR3. The predictive significance of FPR3 was evaluated independently in gliomas using data from TCGA and CGGA datasets, leading to the development of a prognostic nomogram. Immunohistochemistry and Western blot analysis confirmed FPR3 expression in gliomas. Lastly, the CCK-8 and wound-healing assays were employed to assess the impact of FPR3 on the proliferation and metastasis of GBM cell lines. In numerous cancer types, heightened FPR3 expression correlated with adverse outcomes, immune cell infiltration, immune checkpoints, TMB, and MSI. In glioma, FPR3 emerged as a notable risk factor, with the prognostic model effectively forecasting patient results. The potential biological relevance of FPR3 was confirmed in glioma, and it was shown to have significant involvement in the processes of glioma growth, immune infiltration, and metastasis. Our results imply a potential association of FPR3 with tumor immunity, indicating its viability as a prognostic indicator in glioma.
已知甲酰肽受体3（FPR3）在多种癌症类型的进展中具有重要意义。尽管如此，其在泛癌数据集中的生物学意义尚未得到研究。在本研究中，我们详细分析了FPR3在不同类型癌症中的表达谱、基因改变、预后意义、免疫相关特征、甲基化状态、肿瘤突变负担（TMB）和微卫星不稳定性（MSI）。我们利用TISCH的单细胞数据来识别与FPR3密切相关的免疫细胞。使用来自TCGA和CGGA数据集的数据，在胶质瘤中独立评估FPR3的预测意义，从而开发出一种预后列线图。免疫组织化学和蛋白质印迹分析证实了FPR3在胶质瘤中的表达。最后，采用CCK-8和伤口愈合试验来评估FPR3对胶质母细胞瘤细胞系增殖和转移的影响。在多种癌症类型中，FPR3表达升高与不良预后、免疫细胞浸润、免疫检查点、TMB和MSI相关。在胶质瘤中，FPR3是一个显著的危险因素，预后模型能够有效预测患者的预后。FPR3在胶质瘤中的潜在生物学相关性得到证实，并且显示其在胶质瘤生长、免疫浸润和转移过程中具有重要作用。我们的结果表明FPR3与肿瘤免疫可能存在关联，表明其作为胶质瘤预后指标的可行性。
